Akorn, Inc. and Bioniche Pharma have entered into a five-year commercial manufacturing and supply agreement for two undisclosed pharmaceutical products. Under the terms of the agreement, Akorn will be responsible for the manufacturing and supply of the two injectable products. The two products are expected to launch in the second half of this year.     Arthur S. Przybyl, Akorn’s president and chief executive officer, stated, “We are very pleased to have been selected as the contract manufactu...